Business Context and Reporting Period
This Form 8-K, dated November 25, 2025, reports on Omeros Corporation's completion of a strategic asset sale and a significant debt restructuring. The filing details the closing of an Asset Purchase and License Agreement with Novo Nordisk Health Care AG and the simultaneous termination of the Company's Credit Agreement.
Key Financial Metrics and Transaction Details
- Upfront Cash Proceeds: $240.0 million received from Novo Nordisk at closing.
- Debt Repayment: Approximately $72.6 million of the upfront payment was used to retire all outstanding obligations under the Credit Agreement. This included a $67.1 million term loan, a $3.4 million mandatory prepayment premium, $2.0 million in incurred interest, and approximately $0.1 million in transaction expenses.
- Liquidity Impact: The debt repayment released a $25.0 million minimum cash covenant, making these funds available for working capital.
- Future Consideration: Potential milestone payments total up to $1.81 billion ($510 million for development/approval and $1.3 billion for sales), bringing the total potential deal value to $2.1 billion.
- Royalties: Omeros is eligible for tiered royalties on annual net sales ranging from high single-digit to high-teens percentages.
- Share Repurchase: The Board approved an indefinite term program to repurchase up to $100.0 million of common stock.
Material Changes Versus Prior Period
The most significant change is the divestiture of exclusive global rights to zaltenibart (OMS906) and related compounds to Novo Nordisk. This transaction fundamentally alters the Company's asset base and future revenue streams, shifting from direct development/commercialization of this specific asset to a royalty and milestone-based model. Additionally, the Company has moved from a leveraged position with restrictive covenants to a debt-free status regarding the Credit Agreement, significantly improving financial flexibility.
Outlook, Management Commentary, and Risks
Management views the transaction as a strategic move to maximize the potential of zaltenibart for rare blood and kidney disorders by leveraging Novo Nordisk's capabilities. Omeros retains rights to its MASP-3 small-molecule program and "grandfathered" MASP-3 antibodies. The Company has entered a Transition Services Agreement to facilitate the asset transfer, with Novo Nordisk reimbursing associated costs. The filing includes standard forward-looking statement disclaimers regarding regulatory processes, commercialization risks, and the uncertainty of achieving milestone payments.
Investor Verification Checklist
- Verify the specific terms and conditions of the milestone payments in the full Asset Purchase and License Agreement.
- Review the unaudited pro forma financial statements (Exhibit 99.2) to understand the projected financial position post-transaction.
- Confirm the scope of retained rights regarding the MASP-3 small-molecule program and "grandfathered" antibodies.
- Monitor the execution of the $100.0 million share repurchase program and its impact on share count.
- Assess the duration and cost structure of the Transition Services Agreement.